Silikotac Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease NOVA awarded €2.4 million to leverage Jinko®, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease   1 2 - to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of action of inolimomab   ElsaLys Biotech utilising in silico studies to accelerate the European approval of inolimomab in both adult and paediatric populations with this rare...

Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease NOVA awarded €2.4 million to leverage Jinko, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease Research academic teams of the consortium - Institut de Recherche Saint Louis 1 2 - to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of action of inolimomab ElsaLys Biotech utilising in silico studies to accelerate the European approval...